U.S. stock night market fluctuations: Adlai Nortye rose 3.55% in the night market, analysts' hold ratings fail to boost market confidence, funds flow to other stocks

U.S. Stock Night Market Movements Adlai Nortye rose 3.55% in the night market. Based on recent key news: On April 16, MarketBeat pointed out that Adlai Nortye was not included in the list of five stocks recommended by top analysts. Although analysts rated Adlai Nortye as a hold, the market's lack of confidence in its future performance led to stock price fluctuations. On April 15, analysts continued to maintain a hold rating on Adlai Nortye, believing that five other stocks had more investment value. This rating failed to stimulate investor buying interest, affecting stock price performance. The market's lack of confidence in Adlai Nortye led funds to flow into other stocks. Stocks with High Trading Volume in the Industry Immutep rose 15.92% in the night market. Based on recent key news: On April 16, Immutep received FDA orphan drug designation for the treatment of soft tissue sarcoma. This news drove the stock price up, as the designation supports potential late-stage development. Source: Public Technologies On April 15, Immutep's Eftilagimod Alfa reached its primary endpoint in Phase II trials, demonstrating good safety and efficacy, further enhancing market confidence. Source: Public Technologies On April 14, Immutep executive Marc Voigt disclosed holding a significant amount of company shares, showing management's confidence in the company's prospects. Source: Public Technologies The biotechnology industry has recently been active, with noticeable capital inflows. Moderna rose 0.17% in the night market. Based on recent key news: On April 16, Moderna's MACD indicator showed a golden cross, interpreted by the market as a short-term buying signal, driving the stock price up. The upward trend of the 20-day and 60-day moving averages provides support for short-term upward movement, with investor sentiment positive, anticipating a breakthrough at the 54.68 price level. On April 15, Moderna announced it would release its Q1 2026 financial report on May 1, and market expectations for the report may affect stock price trends. On April 13, analysts rated Moderna as a sell, believing that other stocks had more investment value, which could put pressure on the stock price. Market volatility has increased, and risks need to be monitored. Medicus Pharma rose 29.59% in the night market. Based on recent news: On April 15, Medicus Pharma released a new product announcement, driving the stock price up. According to GlobeNewswire, the company announced new drug development progress, and the market reacted positively, leading to a significant increase in stock price during night trading On April 15th, Benzinga Pro data showed that Medicus Pharma's stock price rose by 9.45% in pre-market trading. This early increase supported subsequent after-hours trading, further driving the overall rise in stock price. There are no other significant news recently. The pharmaceutical industry has performed strongly lately, with noticeable capital inflows